The Strengths of the University Hospital Model in Research and Innovation : The French model

This abstract has open access
Abstract Description

The university hospital model represents far more than a collection of separate functions. It embodies a deeply interconnected ecosystem where the boundaries between patient care, education, research, and innovation blur into a cohesive whole. This symbiosis creates unique value impossible to replicate in standalone institutions. The true power of the university hospital model emerges from the multiplicative effects of these integrated domains: Accelerated Therapeutic Evolution: New treatments improve faster than in isolated systems Dynamic Knowledge Networks: Information flows rapidly across traditional boundaries Problem-Solving Density: Concentration of diverse expertise increases solution generation capacity Resilient Healthcare Infrastructure: Adaptability to new challenges through embedded research capabilities. This comprehensive integration creates not just incremental improvements but transformative possibilities for healthcare advancement. The university hospital stands as society's most sophisticated mechanism for simultaneously delivering today's care while creating tomorrow's medicine. 

The Hospital Clinical Research Program (PHRC) constitutes a fundamental pillar of the French health research system, representing a unique model of public investment in clinical innovation. This national initiative presents several distinctive strengths that make it an essential catalyst for medical and scientific progress like independence from the pharmaceutical industry: exploration of clinical questions without direct commercial interest, head-to-head studies without funding bias, generation of independent data on treatment efficacy and safety. The strength of the PHRC is explained by the networking of the 32 French university hospitals (CHUs) and cancer centers. The French government allocates 150 million euros per year to the PHRC through competitive calls for proposals, with an average funding level of 800,000 euros, primarily for multicenter randomized placebo-controlled clinical trials. The majority of the work is published in the best specialty journals and in top-tier journals (NEJM, Lancet, JAMA, BMJ). The PHRC is a powerful tool because all major hospitals across the national territory are networked with clinical research departments that operate in the same manner. Finally, the costs of studies (project managers, clinical research technicians, biostatistics, placebo, physician time, nursing staff, etc.) are the same for each center participating in a PHRC project, with an additional premium for the coordinating center of the study.


Submission ID :
HAC1341
Submission Type
President of the national committee for public hospital research (CNCR); chief medical officer at University Hospital of Nantes, Fr.
,
University Hospital Of Nantes

Abstracts With Same Type

Submission ID
Submission Title
Submission Topic
Submission Type
Primary Author
HAC1170
Speaker
Dr Koon-ming Michael KAM
HAC1216
Speaker
Prof Kwok-leung CHEUNG
HAC1297
Speaker
Prof Axel HOFMANN
27 visits